Closing Summary and Future Directions in the Field of EGFR-Mutant mNSCLC

The program concludes with a comprehensive review of combination therapy benefits and emerging innovations for EGFR-mutant mNSCLC. The panel emphasizes the significant survival advantages of first-line combination therapy with amivantamab plus lazertinib, including durable systemic and intracranial disease control. Practical considerations, such as adverse event management, therapy administration, and patient convenience, are highlighted to support implementation in routine clinical practice. Subcutaneous formulations are discussed as a major advance, reducing infusion times, improving patient adherence, and enhancing overall satisfaction. The panel underscores the importance of patient-centered care, shared decision-making, and education regarding treatment trade-offs to ensure informed therapy selection. Long-term management strategies are reiterated, emphasizing the need to maximize first-line therapy benefit and prepare for limited second-line options. The session concludes by summarizing the overall improvements in survival, quality of life, and clinical outcomes achieved through combination therapy, while highlighting ongoing research and innovations that may further refine treatment strategies.